BioCentury
ARTICLE | Company News

Karo Bio, Alkem in deal for eprotirome

April 26, 2011 11:54 PM UTC

Karo Bio AB (SSE:KARO) granted Alkem Laboratories Ltd. (Mumbai, India) exclusive rights to commercialize metabolic candidate eprotirome in India and other Asia-Pacific and African markets. Alkem plans to conduct an Indian Phase III trial of the thyroid hormone receptor agonist to treat primary hyperlipidemia. Karo Bio will have access to use data from the Indian trial for its MAA in the EU for eprotirome to treat heterozygous familial hypercholesterolemia (HeFH). Karo Bio plans to start a Phase III trial in the HeFH indication next quarter. ...